drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Gene-modified, CD19-directed T-cell therapy (engineered cytotoxic T cells; single infusion ~3×10^6 cells/kg) designed to deplete CD19+ B cells to reduce autoantibody production and modulate humoral immunity in refractory autoimmune diseases.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Gene‑modified autologous T cells expressing an anti‑CD19 chimeric receptor recognize and kill CD19+ B cells and plasmablasts, producing B‑cell depletion that lowers autoantibody production and modulates humoral immunity in refractory autoimmune disease.
drug_name
YTS109
nct_id_drug_ref
NCT06379646